Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMVT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Batoclimab | Thyroid Eye Disease | Phase 3 · NCT05517447 | Terminated |
| Imeroprubart (IMVT-1402) | Generalized Myasthenia Gravis | Phase 3 · NCT07039916 | Recruiting |
| Batoclimab 680 milligrams (mg) subcutaneous… | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 · NCT05581199 | Terminated |
| IMVT-1401 | Graves Disease | Phase 2 · NCT05907668 | Completed |
| RVT-1401 | Myasthenia Gravis | Phase 2 · NCT03863080 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMVT holds $722.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $103.8M/quarter from operations, an estimated runway of 20.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMVT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 5%+ holder (13D) | 113,327,007 | 54.76% | 2025-12-12 |
| Frank Torti Director · +88,325 options |
Insider | 1,009,228 | 0.49% | 2026-04-07 |
| Eric Venker Chief Executive Officer, Director · +1.26M options |
Insider | 257,075 | 0.12% | 2026-10-01 |
| Tiago Girao Chief Financial Officer · +283,505 options |
Insider | 234,192 | 0.11% | 2026-10-28 |
| Melanie Gloria Chief Operating Officer · +121,063 options |
Insider | 217,060 | 0.10% | 2026-10-07 |
| Jay S Stout Chief Technology Officer · +96,851 options |
Insider | 198,937 | 0.10% | 2026-10-21 |
| Tuyl Christopher Van Chief Legal Officer · +113,527 options |
Insider | 175,218 | 0.08% | 2026-10-07 |
| Atul Pande Director · +69,242 options |
Insider | 136,731 | 0.07% | 2026-11-11 |
| Douglas J. Hughes Director · +7,061 options |
Insider | 134,653 | 0.07% | 2026-04-07 |
| Andrew J. Fromkin Director · +7,061 options |
Insider | 74,382 | 0.04% | 2026-05-28 |
| Jake Bauer Director · +7,061 options |
Insider | 38,896 | 0.02% | 2026-04-07 |
| Robert Graham Susman Director · +7,061 options |
Insider | 36,394 | 0.02% | 2026-05-01 |
Share count 206,947,758 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMVT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →